Contrasting Salix Pharmaceuticals (SLXP) & Its Rivals

Salix Pharmaceuticals (NASDAQ: SLXP) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Salix Pharmaceuticals to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Salix Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Salix Pharmaceuticals -2,134.34% -305.24% -25.83%
Salix Pharmaceuticals Competitors -547.39% -39.23% -21.46%

Analyst Recommendations

This is a summary of recent ratings and price targets for Salix Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Salix Pharmaceuticals 0 0 0 0 N/A
Salix Pharmaceuticals Competitors 73 343 1001 29 2.68

As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 22.54%. Given Salix Pharmaceuticals’ competitors higher possible upside, analysts plainly believe Salix Pharmaceuticals has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

65.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.7% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Salix Pharmaceuticals and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Salix Pharmaceuticals N/A N/A -26.55
Salix Pharmaceuticals Competitors $3.02 billion $642.98 million -29.92

Salix Pharmaceuticals’ competitors have higher revenue and earnings than Salix Pharmaceuticals. Salix Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Salix Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Salix Pharmaceuticals’ competitors have a beta of 1.28, suggesting that their average stock price is 28% more volatile than the S&P 500.

Summary

Salix Pharmaceuticals competitors beat Salix Pharmaceuticals on 8 of the 8 factors compared.

Salix Pharmaceuticals Company Profile

Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Its primary product candidates under development include Rifaximin, Methylnaltrexone bromide oral, Ruconest, Rifaximin delayed release or extended intestinal release and Rifaximin soluble solid dispersion (SSD)/next generation.

Receive News & Ratings for Salix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply